- Home
- MUE vs VNDA Comparison
MUE vs VNDA Comparison
Compare MUE & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MUE
- VNDA
- Stock Information
- Founded
- MUE 1999
- VNDA 2002
- Country
- MUE United States
- VNDA United States
- Employees
- MUE N/A
- VNDA N/A
- Industry
- MUE Investment Bankers/Brokers/Service
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- MUE Finance
- VNDA Health Care
- Exchange
- MUE Nasdaq
- VNDA Nasdaq
- Market Cap
- MUE 228.2M
- VNDA 257.8M
- IPO Year
- MUE N/A
- VNDA 2006
- Fundamental
- Price
- MUE $10.35
- VNDA $4.43
- Analyst Decision
- MUE
- VNDA Strong Buy
- Analyst Count
- MUE 0
- VNDA 2
- Target Price
- MUE N/A
- VNDA $16.50
- AVG Volume (30 Days)
- MUE 62.6K
- VNDA 649.7K
- Earning Date
- MUE 01-01-0001
- VNDA 02-13-2025
- Dividend Yield
- MUE 4.09%
- VNDA N/A
- EPS Growth
- MUE N/A
- VNDA N/A
- EPS
- MUE N/A
- VNDA N/A
- Revenue
- MUE N/A
- VNDA $198,772,000.00
- Revenue This Year
- MUE N/A
- VNDA $16.07
- Revenue Next Year
- MUE N/A
- VNDA $24.42
- P/E Ratio
- MUE N/A
- VNDA N/A
- Revenue Growth
- MUE N/A
- VNDA 3.18
- 52 Week Low
- MUE $8.53
- VNDA $3.71
- 52 Week High
- MUE $10.17
- VNDA $6.75
- Technical
- Relative Strength Index (RSI)
- MUE 54.87
- VNDA 44.53
- Support Level
- MUE $10.26
- VNDA $4.34
- Resistance Level
- MUE $10.48
- VNDA $4.65
- Average True Range (ATR)
- MUE 0.08
- VNDA 0.21
- MACD
- MUE 0.00
- VNDA -0.01
- Stochastic Oscillator
- MUE 64.87
- VNDA 36.51
About MUE Blackrock MuniHoldings Quality Fund II Inc.
BlackRock MuniHoldings Quality Fund II Inc is a diversified, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation. The fund seeks to achieve its investment objective by investing in long-term, investment-grade municipal obligations exempt from U.S. federal income taxes.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.